12:00 AM
 | 
Dec 24, 2007
 |  BioCentury  |  Strategy

MorphoSys chronicles

MorphoSys chronicles

MorphoSysshares have risen more than 600% since the end of 2002, when the company annnounced an agreement settling all patent disputes with Cambridge Antibody on the generation of human antibodies using phage display. But compared to an index of its peers, MorphoSys (FSE:MOR) has underperformed. The equal-weighted index includes Crucell (CRXL), Dyax (DYAX), Genmab (CSE:GEN), Immunomedics (IMMU), Medarex (MEDX) and PDL BioPharma (PDLI). Below are selected events tracked against MOR's weekly stock price. Peer group index and MOR's stock price indexed to 1,000 as of Dec. 31, 2001. A. 4/22/02 - MorphoSys (NMarkt:MOR) outlines product strategy: in addition to its...

Read the full 489 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >